Icosavax’s self-assembling vaccine platform

With $51M in series A funds, Icosavax aims to show its de novo protein VLPs make potent vaccines for RSV

Icosavax believes its computationally designed virus-like particles will open the clinically validated vaccine modality to a broader range of infectious diseases. The company expects its $51 million series A round, announced Thursday, to carry its first program through Phase Ib testing.

Virus-like particles (VLPs) -- viral proteins that self-assemble into inert nanoparticles that resemble viral capsids -- have found clinical and commercial success in vaccines including HPV vaccine Gardasil

Read the full 689 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE